Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
- Pfizer Japan Pays 14.8 Billion Yen to Doctors, Medical Institutions in FY2014 under Transparency Guidelines
August 7, 2015
- Japan Pharma Market Up 7.9% in April-June 2015: IMS
August 6, 2015
- 14-Day Limit on Prescriptions Considered Unnecessary from a Safety Standpoint in the US and Europe: Pfizer Pres. Umeda
August 6, 2015
- 80% Generic Target “Completely Unexpected,” and Makes Stable Growth in Japan Market Difficult: Pfizer Pres.
August 6, 2015
- AZ Japan Sales Up 2% to US$977 Million in 1st Half of 2015
August 6, 2015
- Astellas Transfers Muscle Relaxant Suxamethonium to Maruishi on Oct. 1
August 6, 2015
- Naldemedine Demonstrates Favorable Results in 3 PIII Efficacy Studies for Opioid-Induced Constipation: Shionogi
August 5, 2015
- Santen Transfers Anti-Rheumatic Business to Ayumi Pharmaceutical
August 5, 2015
- GSK Suspends Shipment of Anti-MRSA Agent Bactroban
August 5, 2015
- Daiichi Sankyo to Submit 4 Products for Approval in Japan and Overseas through FY2018
August 4, 2015
- Edoxaban Doing Well in Japan, but Off to a Rocky Start in US: Daiichi Sankyo
August 4, 2015
- Astellas Not Keen on Biosimilars: CFO Masuda
August 4, 2015
- Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI
August 4, 2015
- Fuji Pharma to Obtain Marketing Rights for 3 Imaging Agents from Guerbet Japan
August 4, 2015
- Kyowa Kirin to Draw Up 5-Year Midterm Plan Focusing on Development of Global Products: President Hanai
August 4, 2015
- MTPC Files Edaravone for Amyotrophic Lateral Sclerosis in South Korea
August 4, 2015
- Kyowa Kirin’s Pharma Business Sales Up 13% Driven by New Products, Overseas Business in 1st Half of FY2015
August 3, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…